. Author manuscript; available in PMC: 2015 Nov 1.

Published in final edited form as: Cardiol Rev. 2014 Nov-Dec;22(6):263–267. doi: 10.1097/CRD.0000000000000026

Table 1.

Overview of Prevention and Treatment Studies in Cardiac Neonatal Lupus

Study	Intervention	Number of Participants	Outcomes
Izmirly et al¹⁶ Eliasson et al²²	FS use in cases with 2^nd degree AV Block (R)	20 treated, 16 untreated	Higher percentage reverting to 1^st degree AV block or normal sinus rhythm in treated group (p=0.053)
Izmirly²⁷	FS use in cases with hydrops fetalis (R)	27 treated, 10 untreated	Lower 6 month mortality in treated group (p=0.059)
Jaeggi²¹	FS use in cases at diagnosis of heart block (R)	21 treated, 16 untreated	Lower 1 year mortality in treated group (p<0.02)
Eliasson²²	FS use in cases with 2^nd and 3^rd degree AV block (R)	67 treated, 108 untreated	No significant difference in mortality between groups
Buyon et al⁴³ Pisoni et al⁴⁶	IVIG 400 mg/kg q3weeks from GW 12–24 in mothers with previous cardiac NL child (P)	33 treated	6 cases of cardiac NL (18% recurrence rate)
Izmirly⁵⁵	HCQ exposure throughout pregnancy in mothers with previous cardiac NL child (R)	40 treated, 217 untreated	Decreased recurrence rate of cardiac NL in treated group (p=0.050)

FS = Fluorinated Steroids; AV = atrioventricular; IVIG = Intravenous Immunoglobulin; HCQ = Hydroxychloroquine; R = Retrospective Analysis; P = Prospective Study; GW = ________________________________